证券代码：600525 证券简称：ST长园 公告编号：2025078 长园科技集团股份有限公司 （1）公司将于2025年9月25日召开2025年第五次临时股东大会审议补选董事相关议案，股东大会是否审 议通过相关议案存在不确定性。 （2）公司2023年度、2024年度存在时任董事长控制的企业通过第三方非经营性占用资金的情况，因非 经营性占用公司资金事项，公司内部控制存在重大缺陷，上会会计师事务所对公司出具了否定意见的 《2024年度内部控制审计报告》，公司A股股票自2025年4月30日起被实施其他风险警示。截至目前， 资金占用方尚有资金占用利息1,958.98万元未支付；公司按照董事会关于非标准意见内部控制审计报告 的说明落实各项措施、开展内部控制整改工作。请广大投资者注意投资风险。 一、股票交易异常波动的具体情况 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 公司股票价格于2025年9月15日、9月16日、9月17日连续三个交易日内日收盘价格涨幅偏离值累计超 过12%，根据《上海证券 ...

Core Viewpoint - Guangdong Jiaying Pharmaceutical Co., Ltd. is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure, leading to significant stock price declines and market capitalization loss [1][3]. Financial Performance - As of December 31, 2024, the company reported revenue of 376 million yuan, a year-on-year decrease of 29.46%, and a net profit attributable to shareholders of 20.61 million yuan, down 39.94% year-on-year [4]. Internal Control Issues - The investigation was triggered by major internal control deficiencies, highlighted in the company's self-evaluation report, which received a qualified opinion from Zhonghua Accounting Firm [6]. - From September 2024 to January 2025, Jiaying Pharmaceutical's wholly-owned subsidiary transferred a total of 170 million yuan to related party Hunan Yaojuneng Pharmaceutical Co., Ltd. without board approval, using a "beginning of month transfer, end of month return" method to obscure the transactions [6]. - In the fourth quarter of 2024, the company engaged in related party transactions totaling 10.39 million yuan with its second-largest shareholder and other related parties, failing to follow proper board review and disclosure procedures [6].

Core Viewpoint - The company HuLuWa (605199.SH) has reported significant financial issues, including major internal control deficiencies, leading to a substantial decline in revenue and profits for 2024 [1][2][7]. Financial Performance - In 2024, HuLuWa achieved revenue of 1.414 billion yuan, a year-on-year decrease of 21.26% [4]. - The net profit attributable to shareholders was a loss of 274 million yuan, a year-on-year decline of 2629.23% [4]. - The net profit after deducting non-recurring items was a loss of 325 million yuan, down 2250.82% year-on-year [4]. - Cumulatively, the losses for 2023 and 2024 reached approximately 339 million yuan [4]. Product Performance - Among the top ten products, only the sales volume of Qiangli Pipa Lu increased, while the other nine products experienced a decline in sales [5]. - Notably, sales volumes for key products such as Changyanning Capsules and Compound Cold Medicine Granules dropped significantly, with reductions of 59.1% and 44.1% respectively [5]. Internal Control Issues - The auditing firm issued a negative opinion on HuLuWa's internal control audit report, indicating significant deficiencies [6][8]. - The company faced administrative regulatory measures from the Hainan Securities Regulatory Bureau due to inaccuracies in financial disclosures [2][7]. - The internal control deficiencies were linked to improper approval processes for significant transactions, raising concerns about the company's financial reporting integrity [8]. Stock Market Impact - Following the negative audit report, HuLuWa's stock will be subject to risk warnings, changing its trading name to "ST HuLuWa" starting April 30 [2][8]. - As of April 28, the stock closed at 13.06 yuan per share, with a total market capitalization of 5.225 billion yuan [8].

Core Viewpoint - Changyuan Group has announced significant changes including a one-day stock suspension, a change in stock name to "ST Changyuan," and the resignation of its president, amid financial difficulties and internal control issues [1][4][7]. Financial Performance - For the fiscal year 2024, Changyuan Group reported a revenue of 7.874 billion yuan, a decrease of 7.22% year-on-year, and a net loss attributable to shareholders of 978 million yuan, a decline of 1216.44% [9][10]. - In Q1 2025, the company recorded a revenue of 1.397 billion yuan, down 15.3% year-on-year, with a net loss of 91.4 million yuan, a decrease of 650.55% [10][12]. - The company did not distribute any cash dividends or bonus shares for 2024, reflecting its financial strain [9]. Internal Control Issues - The annual audit revealed significant internal control deficiencies, particularly regarding the misuse of funds by a related party, Zhuhai Yuntaili Holdings, which had occupied 294 million yuan and 264 million yuan of company funds as of the end of 2023 and 2024, respectively [4][7]. - The company has acknowledged these deficiencies and plans to enhance its internal audit functions to mitigate future risks [7]. Management Changes - The president, Wu Qiquan, has resigned for personal reasons, and Qiao Wenjian has been appointed as the new president [7][9]. Market Reaction - As of April 28, 2025, Changyuan Group's stock price was 3.62 yuan per share, with a decline of 2.16% on that day, resulting in a total market capitalization of 4.8 billion yuan [13].